Expression of Concern
This article is currently under investigation. We strongly recommend that this article is not cited until the investigation is completed.
Research Paper Volume 12, Issue 11 pp 10506—10516

Modification of graphene oxide by angiopep-2 enhances anti-glioma efficiency of the nanoscaled delivery system for doxorubicin

class="figure-viewer-img"

Figure 3. Angiopep-2 polypeptide-modified and doxorubicin-loaded graphene oxide (ANG-Dox-GO) inhibits tumor growth in U87 MG cells. (A) Cell viability of U87 MG cells treated with PBS (control), GO, Dox (30 μg/mL), Dox-GO (containing 30 μg/mL of Dox), and ANG-Dox-GO (containing 30 μg/mL of Dox), respectively, for 24 h and 48 h by MTT assay. (B) Clone number of U87 MG cells treated with PBS (control), GO, Dox (30 μg/mL), Dox-GO (containing 30 μg/mL of Dox), and ANG-Dox-GO (containing 30 μg/mL of Dox), respectively, for 24 h by colony formation assay. *P < 0.05 vs control cells; #P < 0.05 vs Dox; &P < 0.05 vs. Dox-GO.